Anabolic-androgenic steroids
anabolic steroids · AAS · steroids · testosterone · nandrolone · trenbolone · stanozolol · Dianabol · Anavar · roids
What does current UK evidence show?
UK clinical guidance recognises anabolic steroid use and a need for specialist support. Available service and clinical evidence does not establish a reliable current UK population total or a uniform national increase.
Overview
Identity, legal classification, form and pharmacological context
- Drug category
- Image- and performance-enhancing drugs · Medicines
- Common names
- anabolic steroids, AAS, steroids, testosterone, nandrolone, trenbolone, stanozolol, Dianabol, Anavar, roids
- Typical forms
- Injectable preparations, tablets or capsules, and some licensed gels or creams. The group includes testosterone and related compounds; it excludes corticosteroids used for inflammation. Products from unregulated suppliers may have inaccurate labels, substituted ingredients or contamination.
- Routes
- Commonly injected into muscle or swallowed; prescribed formulations may be applied to the skin. A pharmaceutical-looking vial does not establish that its contents are authentic or sterile.
- UK legal classification
- Class CControlled anabolic-androgenic steroids are Class C and generally Schedule 4 Part II. Possession for personal use is excepted from the ordinary possession prohibition; this does not authorise unlawful supply or possession with intent to supply. The personal-use import/export exception requires carriage in person, not ordering by post, courier or freight. The in-person rule commenced on 23 April 2012 in England, Wales and Scotland and on 10 May 2012 under corresponding Northern Ireland regulations. Licensed medicinal products also remain subject to medicines law. Other substances marketed as IPEDs need separate compound-specific checks.Check government source ↗
- Concise pharmacology
- Anabolic-androgenic steroids act at androgen receptors. Their muscle-building and androgenic effects arise from testosterone-like signalling rather than a conventional stimulant ‘high’. Additional androgens can suppress the body's reproductive hormone system. Prescribed replacement treatment for a diagnosed condition and non-medical use require different clinical assessments.
Main harms
Concise clinical and polydrug picture
Possible problems include acne, fluid retention, raised blood pressure, mood changes, agitation and paranoia. Serious cardiovascular events and acute complications of injection can occur. Chest pain, stroke symptoms, collapse, severe psychiatric disturbance or rapidly worsening infection require urgent assessment.
Repeated non-medical use can damage cardiovascular health and reproductive function. Reported harms include abnormal lipids, heart-muscle dysfunction, liver problems, reduced fertility and testicular shrinkage; androgenic changes in women can persist. A 2025 observational study links longer cumulative AAS exposure with adverse cardiovascular findings, but cannot establish individual prognosis or the size of the UK problem.
Dependence can develop, but hormonal suppression after stopping is not itself proof of addiction. Low mood, fatigue, sleep disturbance, reduced sexual function and craving may follow sustained use. Severe depression or suicidal thoughts need urgent support. Endocrine and substance-use assessment should guide care; evidence for specific withdrawal medicines remains limited.
The 2017 UK clinical guidelines identify added cardiovascular and mental-health concerns with cocaine and liver concerns with heavy alcohol use alongside oral steroids. Multiple steroids and other performance-enhancing medicines create additional uncertainty. ‘Cycling’, ‘stacking’ and products sold for ‘post-cycle therapy’ should not be presented as proven protection from harm.
Injecting introduces risks of abscesses, tissue injury and blood-borne viruses when equipment is shared. Intramuscular use still warrants sterile single-use equipment, safe disposal and access to trained advice. Oral use removes injection-specific hazards but does not remove endocrine, cardiovascular or liver toxicity.
Current intelligence status
Assessment, confidence and direction
UK clinical guidance recognises anabolic steroid use and a need for specialist support. Available service and clinical evidence does not establish a reliable current UK population total or a uniform national increase.
Reason: Moderate confidence concerns the established UK service need and documented range of harms. NHS and UK clinical guidance are consistent, and newer observational evidence reinforces cardiovascular concern. National prevalence, product composition and changes over time are less certain. International clinical findings and needle-exchange activity cannot establish a UK-wide increase.
Principal source limits: General patient guidance; risks vary by compound, formulation, exposure and clinical circumstances. An established clinical framework, not a current prevalence estimate; evidence for specific cessation medicines is limited.
Geography and reference periods are given in each linked source card below. The rating is an editorial evidence judgement, not a probability, clinical risk score or TD priority.The assessment reflects the latest linked evidence and is not a universal severity rating.
Operational implications
Evidence-supported prompts for professional response
Commission accessible needle and syringe provision alongside blood-borne virus testing, hepatitis B vaccination and sexual-health referral. Staff need knowledge of image- and performance-enhancing drugs and should ask about body-image concerns without assuming that every user has a psychiatric disorder. Establish routes to primary care, endocrinology and mental-health support. Emergency teams should ask about steroids and other gym-related products when assessing chest pain, collapse, severe mood disturbance or injecting-site infection. Record actual products, duration and co-use rather than relying on the word ‘steroids’. Local service attendances can guide capacity planning but cannot count everyone using AAS.
Record substance, sold identity, route, frequency and combinations; review physical, mental-health and dependence needs.
Use symptom-led assessment and escalate reduced consciousness, seizures, overheating, chest pain or severe agitation.
Triangulate treatment, mortality, testing, hospital and frontline evidence before assigning a local trend.
Related intelligence
Continue into connected platform evidence
Sources & limitations
Direct evidence links, reference periods and status
Anabolic steroid misuse
PublishedReviewed 16 Jan 2026Reference periodCurrent clinical and legal overview
General patient guidance; risks vary by compound, formulation, exposure and clinical circumstances.Drug misuse and dependence: UK guidelines on clinical management, section 7.8
Published2017Reference periodUK clinical guidance on image- and performance-enhancing drugs
An established clinical framework, not a current prevalence estimate; evidence for specific cessation medicines is limited.Needle and syringe programmes (PH52)
Published26 Mar 2014Reference periodService recommendations including IPED users
Guidance supports appropriate service provision; attendance does not measure population prevalence.List of most commonly encountered controlled drugs
PublishedUpdated 1 Apr 2025Reference periodMDA classification and MDR scheduling
Non-exhaustive list; compound-specific statutory definitions and later amendments must also be considered.Misuse of Drugs (Amendment No. 2) (England, Wales and Scotland) Regulations 2012
Published27 Mar 2012Reference periodCommenced 23 Apr 2012
Applies to England, Wales and Scotland; Northern Ireland has corresponding separate regulations.Illicit anabolic steroid use and cardiovascular status
Published2025Reference periodObservational study published 2025
Cross-sectional association is not proof of causation or a UK population risk estimate.Misuse of Drugs (Amendment) Regulations (Northern Ireland) 2012
Published18 Apr 2012Reference periodCommenced 10 May 2012
Amends the Northern Ireland 2002 regulations; the corresponding Great Britain change has a different commencement date.